PYC 001
Alternative Names: PYC-001Latest Information Update: 04 Apr 2023
At a glance
- Originator PYC Therapeutics
- Class Antisense oligonucleotides; Eye disorder therapies; Morpholines; Peptide drug conjugates
- Mechanism of Action OPA1 protein expression stimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Optic atrophy
- Discontinued Diabetic retinopathy
Most Recent Events
- 03 Feb 2023 Discontinued - Preclinical for Diabetic retinopathy in Australia (Intravitreous) (before February 2023) (PYC Therapeutics Pipeline, February 2023)
- 03 Feb 2023 Preclinical trials in Optic atrophy in Australia (Intravitreous) (before February 2023) (PYC Therapeutics Pipeline, February 2023)
- 03 Feb 2023 PYC Therapeutics announces intention to submit IND application with the US FDA for Optic Atrophy in 2024